Overview

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

Status:
Completed

Trial end date:
2019-06-14

Target enrollment:

Participant gender:

Summary

This study compared the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of immune activation (IA) on peripheral blood molecular profiling in participants maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first year post-transplant.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Treatments:

Tacrolimus